138 related articles for article (PubMed ID: 22020069)
1. Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.
Peters PJ; Polle N; Zeh C; Masaba R; Borkowf CB; Oyaro B; Omolo P; Ogindo P; Ndivo R; Angira F; Lando R; Fowler MG; Weidle PJ; Thomas TK
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(2):142-9. PubMed ID: 22020069
[TBL] [Abstract][Full Text] [Related]
2. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
[TBL] [Abstract][Full Text] [Related]
3. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
4. Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
Kondo W; Carraro EA; Prandel E; Dias JM; Perini J; Macedo RL; Cornelsen TC; Sbalquiero R; Sasaki Md
Braz J Infect Dis; 2007 Dec; 11(6):544-8. PubMed ID: 18327464
[TBL] [Abstract][Full Text] [Related]
5. Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.
Minniear TD; Zeh C; Polle N; Masaba R; Peters PJ; Oyaro B; Akoth B; Ndivo R; Angira F; Mills LA; Thomas TK
Pediatr Infect Dis J; 2012 Nov; 31(11):1155-7. PubMed ID: 22772167
[TBL] [Abstract][Full Text] [Related]
6. Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
Aaron E; Kempf MC; Criniti S; Tedaldi E; Gracely E; Warriner A; Kumar R; Bachmann LH
PLoS One; 2010 Sep; 5(9):e12617. PubMed ID: 20838641
[TBL] [Abstract][Full Text] [Related]
7. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
[TBL] [Abstract][Full Text] [Related]
8. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
Ouyang DW; Brogly SB; Lu M; Shapiro DE; Hershow RC; French AL; Leighty RM; Thompson B; Tuomala RE
AIDS; 2010 Jan; 24(1):109-14. PubMed ID: 19926957
[TBL] [Abstract][Full Text] [Related]
9. Nelfinavir and nevirapine side effects during pregnancy.
Timmermans S; Tempelman C; Godfried MH; Nellen J; Dieleman J; Sprenger H; Schneider ME; de Wolf F; Boer K; van der Ende ME;
AIDS; 2005 May; 19(8):795-9. PubMed ID: 15867493
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
[TBL] [Abstract][Full Text] [Related]
11. Safety of nevirapine in pregnancy.
Natarajan U; Pym A; McDonald C; Velisetty P; Edwards SG; Hay P; Welch J; de Ruiter A; Taylor GP; Anderson J
HIV Med; 2007 Jan; 8(1):64-9. PubMed ID: 17305934
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
Ouyang DW; Shapiro DE; Lu M; Brogly SB; French AL; Leighty RM; Thompson B; Tuomala RE; Hershow RC
AIDS; 2009 Nov; 23(18):2425-30. PubMed ID: 19617813
[TBL] [Abstract][Full Text] [Related]
13. [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
Tempelman C; Timmermans S; Godfried MH; Dieleman JP; Boer K; van der Ende ME
Ned Tijdschr Geneeskd; 2004 Oct; 148(41):2021-5. PubMed ID: 15553999
[TBL] [Abstract][Full Text] [Related]
14. Safety issues about nevirapine administration in HIV-infected pregnant women.
Manfredi R; Calza L
J Acquir Immune Defic Syndr; 2007 Jul; 45(3):365-8. PubMed ID: 17592340
[No Abstract] [Full Text] [Related]
15. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
Lyons F; Hopkins S; Kelleher B; McGeary A; Sheehan G; Geoghegan J; Bergin C; Mulcahy FM; McCormick PA
HIV Med; 2006 May; 7(4):255-60. PubMed ID: 16630038
[TBL] [Abstract][Full Text] [Related]
16. Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
Bera E; Mia R
S Afr Med J; 2012 Oct; 102(11 Pt 1):855-9. PubMed ID: 23116743
[TBL] [Abstract][Full Text] [Related]
17. Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
Dong BJ; Zheng Y; Hughes MD; Frymoyer A; Verotta D; Lizak P; Sawe F; Currier JS; Lockman S; Aweeka FT;
AIDS; 2012 Apr; 26(7):833-41. PubMed ID: 22301417
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
Coffie PA; Tonwe-Gold B; Tanon AK; Amani-Bosse C; Bédikou G; Abrams EJ; Dabis F; Ekouevi DK
BMC Infect Dis; 2010 Jun; 10():188. PubMed ID: 20576111
[TBL] [Abstract][Full Text] [Related]
19. Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
Edwards SG; Larbalestier N; Hay P; de Ruiter A; Welch J; Taylor GP; Easterbrook P
HIV Med; 2001 Apr; 2(2):89-91. PubMed ID: 11737384
[TBL] [Abstract][Full Text] [Related]
20. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
; de Vincenzi I
Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
